on this page
Please note: You’ll get an immediate assessment when you request PBS authorities online.
Patient eligibility
The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with burosumab under the National Health Act 1953, section 100 for adult patients with X-linked hypophosphataemia (XLH).
Patients must be eligible for the PBS and meet the relevant restriction criteria.
The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing burosumab.
Section 100 arrangements
Burosumab
This item is only PBS-subsidised for non-admitted patients, day admitted patients or patients on discharge who are attending:
- an approved private hospital
- a public hospital.
This item isn’t PBS-subsidised for public hospital in-patients. You must include the hospital provider number for the authority application.
Treatment specifics
To be eligible for PBS-subsidised treatment with burosumab, patients must be treated by a medical practitioner identifying as at least one of the following specialists:
- paediatric endocrinologist
- paediatric nephrologist
- endocrinologist
- nephrologist.
Authority applications
Applying for initial treatment
Applications for initial authority approval to prescribe PBS-subsidised burosumab to treat XLH can be made either:
- in real time using the Online PBS Authorities system
- by calling the PBS Complex Drugs Programs enquiry line.
Applying for continuing treatment
Applications for continuing authority approval to prescribe PBS-subsidised burosumab to treat XLH can be made either:
- in real time using the Online PBS Authorities system
- by calling the PBS Complex Drugs Programs enquiry line.
More information
Call the PBS Complex Drugs Programs enquiry line for more information.